DR. REBECCA C. KEITH M.D.
Prescription History 1720109010
Internal Medicine - Pulmonary Disease in Denver, CO


Quality Rating: 81.15 out of 100 score

NPI Status: Active since April 03, 2007

Contact Information

1400 JACKSON ST
DENVER, CO
ZIP 80206
Phone: (303) 388-4461
Fax: (303) 270-2206

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. REBECCA C. KEITH M.D., an active Pulmonary Disease specialist practicing in Denver, CO. Our medical registry currently tracks 19 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 742 documented patient claims. Among these therapy options, the most frequently utilized medication is Ofev, which accounts for 125 claims alone.


Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 55
30-Day Fills 80.8
Days Supply 2,072
CO State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills51.2
Peer Average Days Supply1,274
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 37.5% more claims than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,763.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$50.25

State Avg Cost Per Claim

$47.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Alvesco

Generic Formulation: CiclesonideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 210
CO State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills70.3
Peer Average Days Supply2,105
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.7% less volume than the regional standard for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,149.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$296.36

State Avg Cost Per Claim

$182.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ciclesonide is used to prevent and reduce the symptoms (wheezing and shortness of breath) caused by asthma. Controlling asthma symptoms may decrease time lost from work or school. This medication belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. This medication must be taken regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed. Keep track of how often you need to use your quick-relief inhaler, and tell your doctor. If your quick-relief inhaler does not seem to work as well, if you need to use more than usual of your quick-relief inhaler for 2 or more days in a row, or if you need to use more than one full canister of your quick-relief inhaler over a 2-month period, seek immediate medical attention.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 35.0
Days Supply 1,050
CO State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills36.5
Peer Average Days Supply1,070
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,249.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$749.96

State Avg Cost Per Claim

$619.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
CO State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills20.9
Peer Average Days Supply625
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,960.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$227.75

State Avg Cost Per Claim

$285.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 28.6
Days Supply 752
CO State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills29.7
Peer Average Days Supply322
Conservative Utilization

This provider writes prescriptions for this formulation 34.6% less frequently than the standard regional baseline metric for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $260.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.33

State Avg Cost Per Claim

$13.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 40
30-Day Fills 58.0
Days Supply 1,740
CO State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills36.6
Peer Average Days Supply1,094
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 42.9% more claims than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38,992.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$974.80

State Avg Cost Per Claim

$830.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 30
30-Day Fills 48.0
Days Supply 1,440
CO State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills28.1
Peer Average Days Supply796
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.4% more claims than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,871.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$595.71

State Avg Cost Per Claim

$452.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Levalbuterol Tartrate Hfa

Generic Formulation: Levalbuterol TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.6
Days Supply 377
CO State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills19.8
Peer Average Days Supply480
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $954.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$79.53

State Avg Cost Per Claim

$78.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Levalbuterol is used to prevent and treat wheezing and shortness of breath caused by breathing problems (such as asthma, chronic obstructive pulmonary disease). It is a quick-relief drug. Levalbuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. This drug is not approved for use in children younger than 4 years due to increased risk of side effects (such as unusual fast breathing, worsening asthma). Ask your doctor or pharmacist for details.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 37
30-Day Fills 99.0
Days Supply 2,970
CO State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills78.8
Peer Average Days Supply2,347
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $581.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.70

State Avg Cost Per Claim

$19.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Mycophenolate Mofetil

Generic Formulation: Mycophenolate MofetilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 106
30-Day Fills 129.2
Days Supply 3,866
CO State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills47.2
Peer Average Days Supply1,401
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 307.7% higher than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,187.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$86.68

State Avg Cost Per Claim

$176.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.

Therapeutic Applications

Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.

Mycophenolic Acid

Generic Formulation: Mycophenolate SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 27.0
Days Supply 785
CO State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills62.2
Peer Average Days Supply1,856
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.7% less volume than the regional standard for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,233.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$402.57

State Avg Cost Per Claim

$469.73

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.

Therapeutic Applications

Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted kidney. It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new kidney as if it were your own.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 125
30-Day Fills 125.0
Days Supply 3,750
CO State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills40.4
Peer Average Days Supply1,193
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 212.5% higher than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,689,332.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,514.66

State Avg Cost Per Claim

$12,352.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Omeprazole

Generic Formulation: OmeprazoleSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 32.0
Days Supply 960
CO State Average Benchmarks
Peer Average Claims71.0
Peer Average 30-Day Fills170.6
Peer Average Days Supply5,079
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.5% less volume than the regional standard for practitioners inside CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $265.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.59

State Avg Cost Per Claim

$17.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.

Therapeutic Applications

Omeprazole is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers, and may help prevent cancer of the esophagus. Omeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs). If you are self-treating with this medication, over-the-counter omeprazole products are used to treat frequent heartburn (occurring 2 or more days a week). Since it may take 1 to 4 days to have full effect, these products do not relieve heartburn right away. For over-the-counter products, carefully read the package instructions to make sure the product is right for you. Check the ingredients on the label even if you have used the product before. The manufacturer may have changed the ingredients. Also, products with similar brand names may contain different ingredients meant for different purposes. Taking the wrong product could harm you.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 41
30-Day Fills 41.0
Days Supply 1,230
CO State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.3
Peer Average Days Supply593
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 115.8% higher than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $82,300.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,007.33

State Avg Cost Per Claim

$4,520.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 53.6
Days Supply 1,475
CO State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills45.2
Peer Average Days Supply872
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $237.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.59

State Avg Cost Per Claim

$7.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 39
30-Day Fills 77.5
Days Supply 2,260
CO State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills25.8
Peer Average Days Supply389
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 77.3% higher than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $129.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.32

State Avg Cost Per Claim

$6.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 55
30-Day Fills 114.0
Days Supply 3,420
CO State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills42.0
Peer Average Days Supply1,257
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 103.7% higher than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $45,242.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$822.60

State Avg Cost Per Claim

$574.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 52
30-Day Fills 65.0
Days Supply 1,950
CO State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills54.8
Peer Average Days Supply1,637
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.0% more claims than the standard regional baseline profile for CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $42,215.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$811.83

State Avg Cost Per Claim

$888.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 22.0
Days Supply 501
CO State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills24.1
Peer Average Days Supply548
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,623.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$90.19

State Avg Cost Per Claim

$81.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. REBECCA C. KEITH M.D. provides transparency into local medical care patterns within Denver, CO.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.